Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Trodelvy-Immunotherapy & Beyond: Delving Into Clinical Data & Vision to Utilize Combination Therapies to Empower New Heights of ADC Patient Impact

By | 8 June 2026

Contextualizing ADC combinations as the future of effective clinical approaches as more ADCs advance to standard of care oncology settings
Exploring ongoing work into Trodelvy-immunotherapy clinical combinations, focused on urothelial bladder cancer
Highlighting rationale and vision for novel combinations to unlock the prospect of to deliver new heights of ADC powered patient impact